Edgewise Therapeutics Income Statement (2020-2026) | EWTX

Income Statement Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Operating items
Research & Development (Quarter)
7.86M9.88M9.09M11.12M12.40M13.89M16.61M19.88M19.56M23.79M27.68M27.69M30.68M32.22M36.37M36.76M33.56M37.48M43.59M42.65M
Selling, General & Administrative (Quarter)
2.60M3.20M3.73M3.70M4.09M4.37M5.47M5.83M5.78M5.67M6.18M7.06M7.43M8.21M9.17M9.20M9.05M9.38M12.38M11.46M
Operating Expenses (Quarter)
10.46M13.08M12.82M14.83M16.49M18.26M22.08M25.70M25.34M29.45M33.86M34.75M38.11M40.43M45.54M45.96M42.61M46.86M55.98M54.12M
Operating Income (Quarter)
-10.46M-13.08M-12.82M-14.83M-16.49M-18.26M-22.08M-25.70M-25.34M-29.45M-33.86M-34.75M-38.11M-40.43M-45.54M-45.96M-42.61M-46.86M-55.98M-54.12M
EBIT (Quarter)
-10.46M-13.08M-12.82M-14.83M-16.49M-18.26M-22.08M-25.70M-25.34M-29.45M-33.86M-34.75M-38.11M-40.43M-45.54M-45.96M-42.61M-46.86M-55.98M-54.12M
Non-operating items
Interest & Investment Income (Quarter)
0.11M0.13M0.13M0.17M0.42M0.76M2.66M2.87M3.87M3.74M3.72M6.23M6.61M6.30M5.88M5.16M6.50M6.19M5.76M5.10M
Other Non Operating Income (Quarter)
0.11M0.13M0.13M0.17M0.42M0.76M2.66M2.87M3.87M3.74M3.72M6.23M6.61M6.30M5.88M5.16M6.50M6.19M5.76M5.10M
Net income details
EBT (Quarter)
-10.35M-12.95M-12.70M-14.66M-16.07M-17.50M-19.41M-22.84M-21.47M-25.71M-30.14M-28.52M-31.50M-34.13M-39.66M-40.80M-36.12M-40.67M-50.22M-49.01M
Profit After Tax (Quarter)
-10.35M-12.95M-12.70M-14.66M-16.07M-17.50M-19.41M-22.84M-21.47M-25.71M-30.14M-28.52M-31.50M-34.13M-39.66M-40.80M-36.12M-40.67M-50.22M-49.01M
Income from Continuing Operations (Quarter)
-10.35M-12.95M-12.70M-14.66M-16.07M-17.50M-19.41M-22.84M-21.47M-25.71M-30.14M-28.52M-31.50M-34.13M-39.66M-40.80M-36.12M-40.67M-50.22M-49.01M
Consolidated Net Income (Quarter)
-10.35M-12.95M-12.70M-14.66M-16.07M-17.50M-19.41M-22.84M-21.47M-25.71M-30.14M-28.52M-31.50M-34.13M-39.66M-40.80M-36.12M-40.67M-50.22M-49.01M
Income towards Parent Company (Quarter)
-10.35M-12.95M-12.70M-14.66M-16.07M-17.50M-19.41M-22.84M-21.47M-25.71M-30.14M-28.52M-31.50M-34.13M-39.66M-40.80M-36.12M-40.67M-50.22M-49.01M
Net Income towards Common Stockholders (Quarter)
-10.35M-12.95M-12.70M-14.66M-16.07M-17.50M-19.41M-22.84M-21.47M-25.71M-30.14M-28.52M-31.50M-34.13M-39.66M-40.80M-36.12M-40.67M-50.22M-49.01M
Additional items
EPS (Basic) (Quarter)
-0.21-0.26-0.24-0.30-0.32-0.34-0.30-0.36-0.34-0.41-0.47-0.33-0.34-0.36-0.42-0.43-0.34-0.39-0.48-0.46
EPS (Weighted Average and Diluted) (Quarter)
-0.21-0.26-0.24-0.30-0.32-0.34-0.30-0.36-0.34-0.41-0.47-0.33-0.34-0.36-0.42-0.43-0.34-0.39-0.48-0.46
Shares Outstanding (Weighted Average) (Quarter)
49.26M33.54M37.53M49.54M49.62M51.84M53.59M63.27M63.38M63.37M63.72M87.57M93.52M91.64M92.41M95.13M104.94M105.49M102.93M107.12M
Shares Outstanding (Diluted Average) (Quarter)
49.26M33.54M37.53M49.54M49.58M50.35M53.59M63.27M63.32M63.46M63.72M87.57M93.52M93.81M92.41M95.13M104.94M105.49M102.93M107.12M
EBITDA (Quarter)
-10.33M-12.94M-13.19M-16.08M-16.47M-17.34M-18.59M-21.73M-21.77M-25.59M-29.62M-29.48M-31.69M-32.02M-40.29M-40.82M-36.31M-40.17M-50.24M-49.94M
Shares Outstanding (Quarter)
49.26M49.30M49.50M49.56M49.78M63.21M63.26M63.27M63.46M63.46M70.45M93.28M93.64M94.41M94.84M95.21M105.34M105.76M106.25M107.48M